Brought to you by 
Gilead gains late-stage cancer candidate through $465mm purchase of YM BioSciences
25 Feb 2021
Executive Summary
Gilead Sciences Inc. has offered $2.95 per share (an 81% premium), or about $465mm, to purchase cancer and inflammatory disease company YM BioSciences Inc. The Canadian biopharma reported $1mm in revenues for 2012, and had $125mm in cash and cash equivalents as of September 30, 2012.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
- Intra-Biotech Deal
- Payment Includes Cash for Equity
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Gilead gains late-stage cancer candidate through $465mm purchase of YM BioSciences
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice